Evidence map›Paper›PMID 41168399›Full record

ArticlePsychopharmacology2025

Ayahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice.

Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira, Fabiane Dörr, Beatriz Aparecida Passos Bismara Paranhos, Fabiana Pereira Santos, Maurício Yonamine, Raphael Caio Tamborelli Garcia, Larissa Helena Torres, Roberto de Pasquale and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vítor BrunoDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Lídia Emmanuela Wiazowski SpeltaDepartment of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Matheus Lujan PereiraDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Fabiane DörrDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Beatriz Aparecida Passos Bismara ParanhosDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Fabiana Pereira SantosDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Maurício YonamineDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Raphael Caio Tamborelli GarciaDepartment of Pharmaceutical Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo, Diadema, São Paulo, Brazil.
Larissa Helena TorresDepartment of Food and Drugs, School of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.
Roberto de PasqualeDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Rosana CamariniDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. camarini@icb.usp.br.
Tania MarcourakisDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil. tmarcour@usp.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 001Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/19011-9Secretaria Nacional de Políticas sobre Drogas Edital n°01, 26/05/2015
6 · The paper itself

Abstract

rationaleAyahuasca is a brew containing the psychedelic compound N,N-dimethyltryptamine (DMT) and β-carbolines, traditionally consumed in indigenous rituals. Recent studies suggest its potential to reduce depression and anxiety and as an alternative for treating ethanol and tobacco use disorders. However, research on its impact on cocaine use disorder remains limited.

objectiveTo analyze the rewarding effects of ayahuasca and to evaluate its therapeutic application on the reinstatement of cocaine-induced conditioned place preference (CPP) in C57Bl/6 mice.

methodsFirst, we examined if ayahuasca (2.5, 7.5, 12.5 and 15 mg DMT/kg, gavage) could induce CPP. Next, using a choice-based CPP paradigm, we compared the rewarding effects of cocaine (10 mg/kg, i.p.) with a previously established rewarding dose of ayahuasca (15 mg DMT/kg). Finally, we employed a cocaine-induced reinstatement protocol to assess whether ayahuasca could prevent the reactivation of cocaine-associated contextual preference. Therefore, mice were conditioned with cocaine and subsequently treated with water or ayahuasca (12.5 or 15 mg DMT/kg). Following a cocaine challenge, reinstatement of cocaine-induced CPP was evaluated.

resultsOur findings showed that while ayahuasca induced rewarding effects with the higher dose tested, these were less pronounced than those of cocaine. Moreover, ayahuasca treatment effectively prevented the cocaine-induced CPP reinstatement.

conclusionThese findings support the therapeutic potential of ayahuasca in the context of cocaine use disorder.

Indexed as

AddictionAyahuascaCocaine use disorderConditioned place preferencePsychedelicsRewarding

Identifiers

PMID41168399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.